{"entity":{"id":"idea-reg-biosimilar-first-default-switching","kind":"idea","name":"Biosimilar-first defaults and payment parity in every cancer day unit","aka":[],"tldr":"Cheaper copies of biological cancer drugs exist but are used far less in some countries than others. Making them the default choice saves billions with no loss of benefit.","summary":"NHS England moved most patients to trastuzumab and rituximab biosimilars within a year of launch through commissioning defaults and shared savings; US uptake was slower because reimbursement incentives favoured the originator. The proposal is a bundle of implementation measures for every payer: prescribing systems default to the lowest-cost interchangeable biologic, payment parity so clinics do not lose revenue by switching, pharmacist-led switching protocols with patient information, and public reporting of biosimilar share by centre.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)","url":"https://doi.org/10.1038/nrclinonc.2017.31"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["trastuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":["paper-prasad-nat-rev-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"The bundle raises biosimilar share for oncology monoclonals above 80% within 12 months of launch in adopting systems, saving at least 30% of prior spend on those molecules with no change in clinical outcomes.","rationale":"Biosimilar uptake is a behavioural and incentive problem, not a scientific one; where defaults and incentives were aligned, switching was fast and safe.","test":"Compare biosimilar share and spend between health systems adopting the bundle and matched systems that do not, over the first two years of each new oncology biosimilar launch.","maturity":"being-tested-at-scale","actor":"payer","cost":"small","horizonYears":2},"route":"/ideas/idea-reg-biosimilar-first-default-switching/","neighbours":{"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}